⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 1, 2025

Supplemental Table 1 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy

Howard L. Li Soren Charmsaz Mari Nakazawa Stephanie Alden Madelena Brancati James M. Leatherman Ervin Griffin Hua‐Ling Tsai Nicole Groß Christopher J. Thoburn Alexei Hernandez Erin M. Coyne Sarah M. Shin Royce P. Lee Evan J. Lipson Burles A. Johnson Aliyah Pabani Yasser Ged Marina Baretti Julie R. Brahmer Jean Hoffman‐Censits Tanguy Y. Seiwert Daniel J. Zabransky Jennifer N. Durham Elizabeth M. Jaffee G. Scott Chandler Brittany L. Adler Won Jin Ho Chester Kao Mark Yarchoan

View Full Paper

Ask AI

Bookmark

Share

Key Points

Immune activation signatures notably correlate with fatigue levels in cancer patients undergoing therapy.
The cohort includes diverse cancer types and corresponding treatment regimens as indicated in Supplemental Table 1.
Treatment regimens focus on immune checkpoint inhibitors, which play a critical role in managing cancer.
Findings highlight the need for understanding fatigue in cancer therapies to improve patient quality of life.

Implication

Supplemental analysis reveals fatigue correlations in cancer patients receiving immune checkpoint inhibitor therapy.

Abstract

Supplemental Table 1 shows cancer types and treatment regimens represented in the cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a217c3 https://doi.org/10.1158/2767-9764.30256038

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Table 3 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy2025
2Supplemental Table 5 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy2025
3Supplemental Table 2 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy2025
4Supplemental Table 6 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy2025
5Supplemental Table 4 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy2025